4-羟基吡咯烷-2-羧酸乙酯 | 1079350-28-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-羟基吡咯烷-2-羧酸乙酯
• 英文名称: L-hydroxyproline ethylate
• 英文别名: 2-ethoxycarbonyl-4-hydroxypyrrolidine；Ethyl 4-hydroxypyrrolidine-2-carboxylate
• CAS: 1079350-28-9
• 化学式: C₇H₁₃NO₃
• 分子量: 159.185
• InChiKey: JMHQESARJMGVCZ-UHFFFAOYSA-N

物化性质

• 沸点：
  262.3±40.0 °C(Predicted)
• 密度：
  1.171±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-羟基吡咯烷-2-羧酸乙酯 、 乙烯亚胺 生成 7-hydroxy-3,4,6,7,8,8a-hexahydro-2H-pyrrolo[1,2-a]pyrazin-1-one
  参考文献：
  名称：

  ITO, YASUO;KATO, XIDEHO;OGAVA, NOBUO;YAMANISI, TEHRUSATO;KOSINAKA, EHJITI+

  摘要：

  DOI：

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS POUR LEUR UTILISATION
  申请人：SPINIFEX PHARM PTY LTD

  公开号：WO2013102242A1

  公开（公告）日：2013-07-11

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

  本发明涉及用于拮抗血管紧张素II型2（AT2）受体的杂环化合物。更具体地，本发明涉及吡咯烷和氮杂环丙烷化合物，含有它们的组合物以及它们在治疗或预防与AT2受体功能相关的疾病或疾病的方法中的使用，包括神经病性疼痛、炎症性疼痛、与神经元过敏、神经传导速度受损、细胞增殖紊乱、骨吸收和骨形成之间失衡以及与异常神经再生相关的疾病。
• [EN] AMINO ACID AND PEPTIDE CONJUGATES OF ARYLALKYLIC ACIDS FOR COSMETIC USE<br/>[FR] AMINOACIDE ET PEPTIDE CONJUGUÉS D'ACIDE ARYL-ALKYLE DESTINES A ETRE UTILISES EN COSMETIQUE
  申请人：DSM IP ASSETS BV

  公开号：WO2005092850A1

  公开（公告）日：2005-10-06

  The invention provides novel compounds of general formula (I), wherein R1, R2 and R3 are independently hydrogen, OR4, C1-C6 alkyl or C2-C6 alkenyl, R4 is hydrogen, C1-C6 alkyl or C2-C6 alkenyl, -N-(AA) represents the residue of an amino acid or of a peptide which is bonded over the N-terminus of the amino acid or the peptide and the peptide is composed of 2 to 6, that means 2, 3, 4, 5 or 6, amino acids, wherein the C-terminus of the amino acid or the peptide is optionally esterified with a C1-C16 hydrocarbon moiety and n is an integer of 1 to 5. The compounds are in particular useful for cosmetic applications.

  该发明提供了一般式（I）的新化合物，其中R1、R2和R3分别是氢、OR4、C1-C6烷基或C2-C6烯基，R4是氢、C1-C6烷基或C2-C6烯基，-N-(AA)代表氨基酸或肽的残基，该残基与氨基酸或肽的N-末端结合，该肽由2至6个氨基酸组成，即2、3、4、5或6个氨基酸，其中氨基酸或肽的C-末端可以选择性地与C1-C16烃基酯化，n是1至5的整数。这些化合物特别适用于化妆品应用。
• [EN] ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS<br/>[FR] COMPOSES MODULATEURS DE RECEPTEUR D'ANDROGENES ET PROCEDES
  申请人：LIGAND PHARM INC

  公开号：WO2005090282A1

  公开（公告）日：2005-09-29

  Provided herein are compounds having a structure selected from among Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) and Formula (VI) that are androgen receptor modulators and/or androgen receptor binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.

  本文提供了具有以下结构的化合物，这些结构选自公式(I)、公式(II)、公式(III)、公式(IV)、公式(V)和公式(VI)，这些化合物是雄激素受体调节剂和/或雄激素受体结合剂。还公开了制备和使用这些化合物的方法，包括但不限于将这些化合物用于治疗各种疾病的方法。
• FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
  申请人：Andrews Martin James Inglis

  公开号：US20090286798A1

  公开（公告）日：2009-11-19

  Novel[1.2.4]triazolo[1,5-a]pyrazine and imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.

  揭示了具有以下表示的公式的新型[1.2.4]三唑并咪唑[1,2-a]吡嗪化合物：这些化合物可以制备为药物组合物，并可用于哺乳动物包括人类的预防和治疗多种疾病，包括但不限于疼痛、炎症等。
• FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF
  申请人：MEDIVATION TECHNOLOGIES, INC.

  公开号：US20140179668A1

  公开（公告）日：2014-06-26

  Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.

  提供了融合嘧啶化合物作为激酶抑制剂，如多激酶抑制剂。提供了融合嘧啶化合物作为IGF-IR抑制剂。这些化合物可用于治疗癌症的方法。还提供了含有融合嘧啶化合物和药用载体的药物组合物，以及含有融合嘧啶化合物或其盐和使用说明的试剂盒，例如用于治疗癌症的方法。